- Dec 2006
- Business started as JapanBridge
- Jun 2007
- Cooperation Agreement with Kyowa Hakko Kogyo Co., Ltd. (currently, Kyowa Hakko Kirin Co., Ltd.) in oncology
- Jan 2008
- Establishment of Medical & Scientific Advisory Board
- May 2008
- License Agreement with ProStrakan for exclusive rights to Sancuso® in Japan, China, and other Asian territories
- Sep 2008
- Company name changed to Solasia Pharma K.K.
- Apr 2009
- Corporate office moved to Shiodome Building (Tokyo)
- Jul 2009
- Completion of SP-01 (Sancuso®) Japanese Phase I study
- Feb 2010
- License Agreement with Kyowa Hakko Kirin Co., Ltd. for the sublicense of Sancuso® in Taiwan, Hong Kong, Singapore & Malaysia
- Mar 2011
- License Agreement with ZIOPHARM Oncology Inc. for exclusive rights to darinaparsin in Japan, China, and other Asian territories
- Dec 2011
- Open Beijing Representative Office in China
- Jan 2013
- Open Shanghai Office in China
- Nov 2013
- Completion of SP-01 (Sancuso®) clinical pharmacological study targeting Chinese healthy adult patient in China
- Dec 2013
- Completion of subject enrollment in SP-02L (darinaparsin injection) Phase I study targeting Korean cancer patient
- May 2014
- Completion of SP-01 (Sancuso®) Phase III study targeting cancer patient with chemotherapy-induced nausea and vomiting in China
- Jun 2014
- Filing of New Drug Application (NDA) SP-01 (Sancuso®) in China
- Jul 2014
- License Agreement with ZIOPHARM Oncology Inc. for global license and collaboration for darinaparsin
- Aug 2014
- Completion of subject enrollment in SP-02L (darinaparsin injection) Phase I study targeting Japanese cancer patient
- Dec 2014
- Establishment of the subsidiary in Shanghai
- Jan 2015
- License Agreement with Meiji Seika Pharma for the development and commercialization of darinaparsin (intravenous formulation) in Japan.
- Mar 2015
- License and Distribution Agreement with Camurus for exclusive license of episil® in Japan and China
- Nov 2015
- License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of Sancuso® in China excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau and Taiwan.
- Mar 2016
- Asian Multinational Phase II study of SP-02L (darinaparsin injection) started
- May 2016
- Filing of New Medical Device Application (NMDA) for episil® in China
- Oct 2016
- Filing of New Medical Device Application (NMDA) for episil® in Japan
- Nov 2016
- License and Collaboration Agreement with Meiji Seika Pharma for episil® in Japan
- Feb 2017
- License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of episil® in China excluding Beijing, Shanghai, Guangzhou and Taiwan
- Mar 2017
- Solasia listed it’s shares to Tokyo Exchange Mothers
- Jul 2017
- Obtained Approval of SP-03 (episil®) in Japan as new medical device
- Nov 2017
- License Agreement with PledPharma for exclusive license of PledOx® in Japan, China and other Asian territories
- May 2018
- Launched episil® (SP-03) in Japan
- Jul 2018
- Obtained Approval of SP-01 (Sancuso®) in China
- Aug 2018
- License and Distribution Agreement with Camurus for exclusive license of episil® in Korea
- Aug 2018
- License and Distribution Agreement with HB Human BioScience SAS for exclusive license of SP-02L (darinaparsin injection) in Latin America (Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, and Guatemala)
- Dec 2018
- Open Guangzhou Office in China
- Feb 2019
- Obtained Approval of SP-03 (episil®) in China as new medical device
- Mar 2019
- Filing of New Medical Device Application (NMDA) for episil® in South Korea
- Mar 2019
- Launched Sancuso® (SP-01) in China
- Jul 2019
- Launched episil® (SP-03) in China
- Oct 2019
- Obtained Commercial Approval of episil® (SP-03) in South Korea
- Dec 2019
- License Agreement with Maruho for commercialization of PledOx® (SP-04) in Japan
- Jan 2020
- License Agreement with Synex for commercialization of episil® (SP-03) in South Korea